AXCAN REPORTS OUTCOME OF ITAX CLINICAL TRIAL

Axcan has announced that results of the ITAX (Itopride) international Phase III clinical trial showed that Itopride, a drug developed for the treatment of functional dyspepsia, did not meet its primary endpoint and, as such, the results did not confirm the efficacy observed in other studies, including the Phase II clinical trial.

The company will continue to analyze the efficacy data from the trial, and this analysis, together with the results of the North American Phase III study, should provide a better understanding of the outcome. These findings will enable the company to decide on the continuation of the ITAX functional dyspepsia program.